Global Daptomycin API Supply, Demand and Key Producers, 2026-2032

November 2026 | 133 pages | ID: GA6F3270412FEN
GlobalInfoResearch

US$ 4,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Daptomycin API market size is expected to reach $ 114 million by 2032, rising at a market growth of 7.2% CAGR during the forecast period (2026-2032).

In 2025, global Daptomycin API capacity 5 Tons, sales reached approximately 4.5 Tons, with an average market price of around 14,890 USD/Kg, industrial gross margin 28%.

Daptomycin is a cyclic lipopeptide antibacterial positioned in the high-value, low-tonnage segment of the anti-infective API industry, where process control and regulatory continuity matter materially more than nominal manufacturing scale. The molecule has the formula C₇₂H₁₀₁N₁₇O₂₆ and a molecular weight of approximately 1,620.7 Da; its antibacterial activity is driven by calcium-dependent insertion into Gram-positive bacterial membranes, rapid membrane depolarization, and subsequent arrest of DNA, RNA and protein synthesis. The relevant industrial market is pharmaceutical-grade API or drug substance rather than finished 350 mg or 500 mg injectable vials, laboratory reagents, analytical standards or fermentation intermediates. Commercial API programs are typically positioned in the high-98% to ≥99% HPLC purity range, but pharmaceutical suitability is governed by a broader specification covering individual and total related substances, residual solvents, water, microbiological attributes and stability. Storage is process- and registration-specific: validated commercial supply chains may use refrigerated conditions of 2–8°C or frozen storage around −20°C, while registered products can carry shelf lives of approximately three years. These requirements make stability data, cold-chain control and manufacturing-change discipline integral to commercial qualification rather than secondary logistics considerations.

The manufacturing platform is built around controlled microbial fermentation followed by a purification train that is substantially more demanding than conventional small-molecule API synthesis. Industrial production uses Streptomyces roseosporus fermentation with controlled fatty-acid precursor feeding, followed by broth clarification, adsorption, ion-exchange chromatography, hydrophobic-interaction or reversed-phase chromatography, membrane concentration and final crystallization or lyophilization. Cost competitiveness is determined by strain productivity, precursor-feed control, impurity formation, chromatographic selectivity, resin productivity and downstream recovery rather than fermenter volume alone. Structurally related lipopeptide congeners are difficult to separate, and incremental purity improvement can require disproportionate resin, solvent and product-loss penalties. As a result, process development is moving upstream: preventing unwanted analogues during fermentation is economically preferable to removing them through additional chromatography. The supply chain therefore extends beyond conventional fermentation nutrients to specialized resins, membrane systems, high-purity solvents, analytical instrumentation and validated clean utilities. Downstream customers are sterile-injectable manufacturers, and supplier onboarding commonly involves analytical comparability, stability packages, quality-system audits, regulatory-file access, validation batches and formal change-control arrangements.

Demand is anchored in serious Gram-positive infections rather than broad outpatient antibiotic use, which gives the product a resilient but clinically bounded commercial profile. Approved applications include complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis. Typical adult regimens include 4 mg/kg every 24 hours for cSSSI and 6 mg/kg every 24 hours for S. aureus bacteremia, with extended dosing intervals in severe renal impairment. Daptomycin is not indicated for pneumonia, which materially limits the addressable clinical setting relative to several broad-spectrum agents. The United States remains one of the most established commercial markets because of early adoption and a mature generic injectable ecosystem, while Europe combines stable institutional demand with stringent GMP and dossier requirements. Japan and other regulated Asian markets place strong emphasis on supplier consistency and change control. China is distinct because it combines a large fermentation-API manufacturing base with an expanding domestic generic-injectable market; inclusion of daptomycin injection in national volume-based procurement has increased the importance of API cost efficiency, forecast reliability and diversified qualified sourcing for finished-dose manufacturers.

Competition is led by a relatively small group of technically experienced anti-infective manufacturers in Europe and China, with regulatory reach and impurity-control capability serving as the primary differentiators. Xellia Pharmaceuticals manufactures the API in Budapest and supports U.S. and European regulatory dossiers, while ACS Dobfar supplies Daptomycin Drug Substance from its Italian anti-infective platform. In China, representative producers include Livzon Group Fuzhou Fuxing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Medicine and the Huadong Medicine manufacturing system, alongside specialized suppliers such as Chongqing Daxin Pharmaceutical and Sichuan Novals Pharmaceuticals. Recent competitive activity is increasingly vertical rather than purely capacity-driven. Zhejiang Medicine’s controlled subsidiary Changhai Pharmaceutical obtained domestic approval for daptomycin API in 2023 after regulatory and FDA-related site work, and Zhejiang Medicine subsequently received Chinese approval for a 0.5 g daptomycin injectable in August 2024 after cumulative R&D spending of approximately RMB15.2 million on the formulation program. The move extends the company from drug-substance production into finished-dose commercialization. In parallel, Huadong Medicine’s manufacturing platform filed a 2024 patent covering high-purity daptomycin crystal preparation, emphasizing shorter purification, lower solvent consumption and industrial scalability, illustrating how process intensification is becoming a competitive asset.

Growth will be shaped by generic penetration, higher-purity API migration, second-source qualification and supply-chain resilience rather than unrestricted expansion in antibiotic consumption. On the demand side, persistent treatment needs for resistant Gram-positive infections support a stable clinical base, while antimicrobial stewardship and therapeutic alternatives such as vancomycin, linezolid and newer anti-MRSA agents cap volume elasticity. On the technology side, strain improvement, precision precursor feeding, online fermentation monitoring, selective chromatography, resin reuse and membrane-based concentration offer the clearest path to lower unit cost without compromising quality. Supply strategies are also changing: flexible multiproduct fermentation sites combined with dedicated critical purification steps and geographically diversified regulatory files are more attractive than large standalone daptomycin lines. Competitive advantage will increasingly reside with manufacturers able to support China, the United States, Europe and selected Asian markets from stable processes and harmonized dossiers. For Chinese suppliers, the most defensible opportunities are higher-purity grades, regulated-market second-source programs, domestic generic-injectable expansion and selective API-to-FDF integration; the principal constraints remain the narrow clinical scope, long customer-validation cycles, environmental-compliance costs, structural spare capacity and trade-policy uncertainty.

Report Scope

This report studies the global Daptomycin API production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Daptomycin API and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Daptomycin API that contribute to its increasing demand across many markets.

Highlights and key features of the study

  • Global Daptomycin API total production and demand, 2021-2032, (kg)
  • Global Daptomycin API total production value, 2021-2032, (USD Million)
  • Global Daptomycin API production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (kg), (based on production site)
  • Global Daptomycin API consumption by region & country, CAGR, 2021-2032 & (kg)
  • U.S. VS China: Daptomycin API domestic production, consumption, key domestic manufacturers and share
  • Global Daptomycin API production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (kg)
  • Global Daptomycin API production by Purity, production, value, CAGR, 2021-2032, (USD Million) & (kg)
  • Global Daptomycin API production by Finished-dose, production, value, CAGR, 2021-2032, (USD Million) & (kg)
This report profiles key players in the global Daptomycin API market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Olon, Xellia Pharmaceuticals, Livzon Group Fuzhou Fuxing Pharmaceutical, Huadong Medicine, Zhejiang Hisun Pharmaceutical, Zhejiang Medicine, Chongqing Daxin Pharmaceutical, Lunan New Times Biotechnology, Sichuan Novals Pharmaceuticals, Fujian Comhony Biotechnology, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Daptomycin API market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (kg) and average price (US$/kg) by manufacturer, by Purity, and by Finished-dose. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Daptomycin API Market, By Region:

  • United States
  • China
  • Europe
  • Japan
  • South Korea
  • ASEAN
  • India
  • Rest of World

Market Segmentation

Global Daptomycin API Market, Segmentation by Purity:

  • ≥99%
  • <99%

Global Daptomycin API Market, Segmentation by Manufacturing Technology:

  • Conventional Fed-batch
  • High-titer Optimized Fermentation

Global Daptomycin API Market, Segmentation by Customer Business Model:

  • Independent Generic Injectable Manufacturers
  • Vertically Integrated Pharmaceutical Groups
  • Others

Global Daptomycin API Market, Segmentation by Finished-dose:

  • 500 mg/vial
  • 350 mg/vial

Companies Profiled:

  • Olon
  • Xellia Pharmaceuticals
  • Livzon Group Fuzhou Fuxing Pharmaceutical
  • Huadong Medicine
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Medicine
  • Chongqing Daxin Pharmaceutical
  • Lunan New Times Biotechnology
  • Sichuan Novals Pharmaceuticals
  • Fujian Comhony Biotechnology
  • Suzhou Biosynergy Pharmaceutical
  • North China Pharmaceutical

Key Questions Answered

1. How big is the global Daptomycin API market?
2. What is the demand of the global Daptomycin API market?
3. What is the year over year growth of the global Daptomycin API market?
4. What is the total value of the global Daptomycin API market?
5. Who are the Major Players in the global Daptomycin API market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY

1.1 Daptomycin API Introduction
1.2 World Daptomycin API Supply & Forecast
  1.2.1 World Daptomycin API Production Value (2021 & 2025 & 2032)
  1.2.2 World Daptomycin API Production (2021-2032)
  1.2.3 World Daptomycin API Pricing Trends (2021-2032)
1.3 World Daptomycin API Production by Region (Based on Production Site)
  1.3.1 World Daptomycin API Production Value by Region (2021-2032)
  1.3.2 World Daptomycin API Production by Region (2021-2032)
  1.3.3 World Daptomycin API Average Price by Region (2021-2032)
  1.3.4 China Daptomycin API Production (2021-2032)
  1.3.5 Europe Daptomycin API Production (2021-2032)
  1.3.6 North America Daptomycin API Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Daptomycin API Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Daptomycin API Major Market Trends

2 DEMAND SUMMARY

2.1 World Daptomycin API Demand (2021-2032)
2.2 World Daptomycin API Consumption by Region
  2.2.1 World Daptomycin API Consumption by Region (2021-2026)
  2.2.2 World Daptomycin API Consumption Forecast by Region (2027-2032)
2.3 United States Daptomycin API Consumption (2021-2032)
2.4 China Daptomycin API Consumption (2021-2032)
2.5 Europe Daptomycin API Consumption (2021-2032)
2.6 Japan Daptomycin API Consumption (2021-2032)
2.7 South Korea Daptomycin API Consumption (2021-2032)
2.8 ASEAN Daptomycin API Consumption (2021-2032)
2.9 India Daptomycin API Consumption (2021-2032)

3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS

3.1 World Daptomycin API Production Value by Manufacturer (2021-2026)
3.2 World Daptomycin API Production by Manufacturer (2021-2026)
3.3 World Daptomycin API Average Price by Manufacturer (2021-2026)
3.4 Daptomycin API Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
  3.5.1 Global Daptomycin API Industry Rank of Major Manufacturers
  3.5.2 Global Concentration Ratios (CR4) for Daptomycin API in 2025
  3.5.3 Global Concentration Ratios (CR8) for Daptomycin API in 2025
3.6 Daptomycin API Market: Overall Company Footprint Analysis
  3.6.1 Daptomycin API Market: Region Footprint
  3.6.2 Daptomycin API Market: Company Product Type Footprint
  3.6.3 Daptomycin API Market: Company Product Application Footprint
3.7 Competitive Environment
  3.7.1 Historical Structure of the Industry
  3.7.2 Barriers of Market Entry
  3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

4.1 United States VS China: Daptomycin API Production Value Comparison
  4.1.1 United States VS China: Daptomycin API Production Value Comparison (2021 & 2025 & 2032)
  4.1.2 United States VS China: Daptomycin API Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Daptomycin API Production Comparison
  4.2.1 United States VS China: Daptomycin API Production Comparison (2021 & 2025 & 2032)
  4.2.2 United States VS China: Daptomycin API Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Daptomycin API Consumption Comparison
  4.3.1 United States VS China: Daptomycin API Consumption Comparison (2021 & 2025 & 2032)
  4.3.2 United States VS China: Daptomycin API Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Daptomycin API Manufacturers and Market Share, 2021-2026
  4.4.1 United States Based Daptomycin API Manufacturers, Headquarters and Production Site (States, Country)
  4.4.2 United States Based Manufacturers Daptomycin API Production Value (2021-2026)
  4.4.3 United States Based Manufacturers Daptomycin API Production (2021-2026)
4.5 China Based Daptomycin API Manufacturers and Market Share
  4.5.1 China Based Daptomycin API Manufacturers, Headquarters and Production Site (Province, Country)
  4.5.2 China Based Manufacturers Daptomycin API Production Value (2021-2026)
  4.5.3 China Based Manufacturers Daptomycin API Production (2021-2026)
4.6 Rest of World Based Daptomycin API Manufacturers and Market Share, 2021-2026
  4.6.1 Rest of World Based Daptomycin API Manufacturers, Headquarters and Production Site (State, Country)
  4.6.2 Rest of World Based Manufacturers Daptomycin API Production Value (2021-2026)
  4.6.3 Rest of World Based Manufacturers Daptomycin API Production (2021-2026)

5 MARKET ANALYSIS BY PURITY

5.1 World Daptomycin API Market Size Overview by Purity: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Purity
  5.2.1 ≥99%
  5.2.2 <99%
5.3 Market Segment by Purity
  5.3.1 World Daptomycin API Production by Purity (2021-2032)
  5.3.2 World Daptomycin API Production Value by Purity (2021-2032)
  5.3.3 World Daptomycin API Average Price by Purity (2021-2032)

6 MARKET ANALYSIS BY MANUFACTURING TECHNOLOGY

6.1 World Daptomycin API Market Size Overview by Manufacturing Technology: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Manufacturing Technology
  6.2.1 Conventional Fed-batch
  6.2.2 High-titer Optimized Fermentation
6.3 Market Segment by Manufacturing Technology
  6.3.1 World Daptomycin API Production by Manufacturing Technology (2021-2032)
  6.3.2 World Daptomycin API Production Value by Manufacturing Technology (2021-2032)
  6.3.3 World Daptomycin API Average Price by Manufacturing Technology (2021-2032)

7 MARKET ANALYSIS BY CUSTOMER BUSINESS MODEL

7.1 World Daptomycin API Market Size Overview by Customer Business Model: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Customer Business Model
  7.2.1 Independent Generic Injectable Manufacturers
  7.2.2 Vertically Integrated Pharmaceutical Groups
  7.2.3 Others
7.3 Market Segment by Customer Business Model
  7.3.1 World Daptomycin API Production by Customer Business Model (2021-2032)
  7.3.2 World Daptomycin API Production Value by Customer Business Model (2021-2032)
  7.3.3 World Daptomycin API Average Price by Customer Business Model (2021-2032)

8 MARKET ANALYSIS BY FINISHED-DOSE

8.1 World Daptomycin API Market Size Overview by Finished-dose: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Finished-dose
  8.2.1 500 mg/vial
  8.2.2 350 mg/vial
8.3 Market Segment by Finished-dose
  8.3.1 World Daptomycin API Production by Finished-dose (2021-2032)
  8.3.2 World Daptomycin API Production Value by Finished-dose (2021-2032)
  8.3.3 World Daptomycin API Average Price by Finished-dose (2021-2032)

9 COMPANY PROFILES

9.1 Olon
  9.1.1 Olon Details
  9.1.2 Olon Major Business
  9.1.3 Olon Daptomycin API Product and Services
  9.1.4 Olon Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.1.5 Olon Recent Developments/Updates
  9.1.6 Olon Competitive Strengths & Weaknesses
9.2 Xellia Pharmaceuticals
  9.2.1 Xellia Pharmaceuticals Details
  9.2.2 Xellia Pharmaceuticals Major Business
  9.2.3 Xellia Pharmaceuticals Daptomycin API Product and Services
  9.2.4 Xellia Pharmaceuticals Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.2.5 Xellia Pharmaceuticals Recent Developments/Updates
  9.2.6 Xellia Pharmaceuticals Competitive Strengths & Weaknesses
9.3 Livzon Group Fuzhou Fuxing Pharmaceutical
  9.3.1 Livzon Group Fuzhou Fuxing Pharmaceutical Details
  9.3.2 Livzon Group Fuzhou Fuxing Pharmaceutical Major Business
  9.3.3 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API Product and Services
  9.3.4 Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.3.5 Livzon Group Fuzhou Fuxing Pharmaceutical Recent Developments/Updates
  9.3.6 Livzon Group Fuzhou Fuxing Pharmaceutical Competitive Strengths & Weaknesses
9.4 Huadong Medicine
  9.4.1 Huadong Medicine Details
  9.4.2 Huadong Medicine Major Business
  9.4.3 Huadong Medicine Daptomycin API Product and Services
  9.4.4 Huadong Medicine Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.4.5 Huadong Medicine Recent Developments/Updates
  9.4.6 Huadong Medicine Competitive Strengths & Weaknesses
9.5 Zhejiang Hisun Pharmaceutical
  9.5.1 Zhejiang Hisun Pharmaceutical Details
  9.5.2 Zhejiang Hisun Pharmaceutical Major Business
  9.5.3 Zhejiang Hisun Pharmaceutical Daptomycin API Product and Services
  9.5.4 Zhejiang Hisun Pharmaceutical Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.5.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates
  9.5.6 Zhejiang Hisun Pharmaceutical Competitive Strengths & Weaknesses
9.6 Zhejiang Medicine
  9.6.1 Zhejiang Medicine Details
  9.6.2 Zhejiang Medicine Major Business
  9.6.3 Zhejiang Medicine Daptomycin API Product and Services
  9.6.4 Zhejiang Medicine Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.6.5 Zhejiang Medicine Recent Developments/Updates
  9.6.6 Zhejiang Medicine Competitive Strengths & Weaknesses
9.7 Chongqing Daxin Pharmaceutical
  9.7.1 Chongqing Daxin Pharmaceutical Details
  9.7.2 Chongqing Daxin Pharmaceutical Major Business
  9.7.3 Chongqing Daxin Pharmaceutical Daptomycin API Product and Services
  9.7.4 Chongqing Daxin Pharmaceutical Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.7.5 Chongqing Daxin Pharmaceutical Recent Developments/Updates
  9.7.6 Chongqing Daxin Pharmaceutical Competitive Strengths & Weaknesses
9.8 Lunan New Times Biotechnology
  9.8.1 Lunan New Times Biotechnology Details
  9.8.2 Lunan New Times Biotechnology Major Business
  9.8.3 Lunan New Times Biotechnology Daptomycin API Product and Services
  9.8.4 Lunan New Times Biotechnology Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.8.5 Lunan New Times Biotechnology Recent Developments/Updates
  9.8.6 Lunan New Times Biotechnology Competitive Strengths & Weaknesses
9.9 Sichuan Novals Pharmaceuticals
  9.9.1 Sichuan Novals Pharmaceuticals Details
  9.9.2 Sichuan Novals Pharmaceuticals Major Business
  9.9.3 Sichuan Novals Pharmaceuticals Daptomycin API Product and Services
  9.9.4 Sichuan Novals Pharmaceuticals Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.9.5 Sichuan Novals Pharmaceuticals Recent Developments/Updates
  9.9.6 Sichuan Novals Pharmaceuticals Competitive Strengths & Weaknesses
9.10 Fujian Comhony Biotechnology
  9.10.1 Fujian Comhony Biotechnology Details
  9.10.2 Fujian Comhony Biotechnology Major Business
  9.10.3 Fujian Comhony Biotechnology Daptomycin API Product and Services
  9.10.4 Fujian Comhony Biotechnology Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.10.5 Fujian Comhony Biotechnology Recent Developments/Updates
  9.10.6 Fujian Comhony Biotechnology Competitive Strengths & Weaknesses
9.11 Suzhou Biosynergy Pharmaceutical
  9.11.1 Suzhou Biosynergy Pharmaceutical Details
  9.11.2 Suzhou Biosynergy Pharmaceutical Major Business
  9.11.3 Suzhou Biosynergy Pharmaceutical Daptomycin API Product and Services
  9.11.4 Suzhou Biosynergy Pharmaceutical Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.11.5 Suzhou Biosynergy Pharmaceutical Recent Developments/Updates
  9.11.6 Suzhou Biosynergy Pharmaceutical Competitive Strengths & Weaknesses
9.12 North China Pharmaceutical
  9.12.1 North China Pharmaceutical Details
  9.12.2 North China Pharmaceutical Major Business
  9.12.3 North China Pharmaceutical Daptomycin API Product and Services
  9.12.4 North China Pharmaceutical Daptomycin API Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.12.5 North China Pharmaceutical Recent Developments/Updates
  9.12.6 North China Pharmaceutical Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 Daptomycin API Industry Chain
10.2 Daptomycin API Upstream Analysis
  10.2.1 Daptomycin API Core Raw Materials
  10.2.2 Main Manufacturers of Daptomycin API Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Daptomycin API Production Mode
10.6 Daptomycin API Procurement Model
10.7 Daptomycin API Industry Sales Model and Sales Channels
  10.7.1 Daptomycin API Sales Model
  10.7.2 Daptomycin API Typical Distributors

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES

Table 1. World Daptomycin API Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Daptomycin API Production Value by Region (2021-2026) & (USD Million)
Table 3. World Daptomycin API Production Value by Region (2027-2032) & (USD Million)
Table 4. World Daptomycin API Production Value Market Share by Region (2021-2026)
Table 5. World Daptomycin API Production Value Market Share by Region (2027-2032)
Table 6. World Daptomycin API Production by Region (2021-2026) & (kg)
Table 7. World Daptomycin API Production by Region (2027-2032) & (kg)
Table 8. World Daptomycin API Production Market Share by Region (2021-2026)
Table 9. World Daptomycin API Production Market Share by Region (2027-2032)
Table 10. World Daptomycin API Average Price by Region (2021-2026) & (US$/kg)
Table 11. World Daptomycin API Average Price by Region (2027-2032) & (US$/kg)
Table 12. Daptomycin API Major Market Trends
Table 13. World Daptomycin API Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (kg)
Table 14. World Daptomycin API Consumption by Region (2021-2026) & (kg)
Table 15. World Daptomycin API Consumption Forecast by Region (2027-2032) & (kg)
Table 16. World Daptomycin API Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Daptomycin API Producers in 2025
Table 18. World Daptomycin API Production by Manufacturer (2021-2026) & (kg)
Table 19. Production Market Share of Key Daptomycin API Producers in 2025
Table 20. World Daptomycin API Average Price by Manufacturer (2021-2026) & (US$/kg)
Table 21. Global Daptomycin API Company Evaluation Quadrant
Table 22. World Daptomycin API Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Daptomycin API Production Site of Key Manufacturer
Table 24. Daptomycin API Market: Company Product Type Footprint
Table 25. Daptomycin API Market: Company Product Application Footprint
Table 26. Daptomycin API Competitive Factors
Table 27. Daptomycin API New Entrant and Capacity Expansion Plans
Table 28. Daptomycin API Mergers & Acquisitions Activity
Table 29. United States VS China Daptomycin API Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Daptomycin API Production Comparison, (2021 & 2025 & 2032) & (kg)
Table 31. United States VS China Daptomycin API Consumption Comparison, (2021 & 2025 & 2032) & (kg)
Table 32. United States Based Daptomycin API Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Daptomycin API Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Daptomycin API Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Daptomycin API Production (2021-2026) & (kg)
Table 36. United States Based Manufacturers Daptomycin API Production Market Share (2021-2026)
Table 37. China Based Daptomycin API Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Daptomycin API Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Daptomycin API Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Daptomycin API Production, (2021-2026) & (kg)
Table 41. China Based Manufacturers Daptomycin API Production Market Share (2021-2026)
Table 42. Rest of World Based Daptomycin API Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Daptomycin API Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Daptomycin API Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Daptomycin API Production, (2021-2026) & (kg)
Table 46. Rest of World Based Manufacturers Daptomycin API Production Market Share (2021-2026)
Table 47. World Daptomycin API Production Value by Purity, (USD Million), 2021 & 2025 & 2032
Table 48. World Daptomycin API Production by Purity (2021-2026) & (kg)
Table 49. World Daptomycin API Production by Purity (2027-2032) & (kg)
Table 50. World Daptomycin API Production Value by Purity (2021-2026) & (USD Million)
Table 51. World Daptomycin API Production Value by Purity (2027-2032) & (USD Million)
Table 52. World Daptomycin API Average Price by Purity (2021-2026) & (US$/kg)
Table 53. World Daptomycin API Average Price by Purity (2027-2032) & (US$/kg)
Table 54. World Daptomycin API Production Value by Manufacturing Technology, (USD Million), 2021 & 2025 & 2032
Table 55. World Daptomycin API Production by Manufacturing Technology (2021-2026) & (kg)
Table 56. World Daptomycin API Production by Manufacturing Technology (2027-2032) & (kg)
Table 57. World Daptomycin API Production Value by Manufacturing Technology (2021-2026) & (USD Million)
Table 58. World Daptomycin API Production Value by Manufacturing Technology (2027-2032) & (USD Million)
Table 59. World Daptomycin API Average Price by Manufacturing Technology (2021-2026) & (US$/kg)
Table 60. World Daptomycin API Average Price by Manufacturing Technology (2027-2032) & (US$/kg)
Table 61. World Daptomycin API Production Value by Customer Business Model, (USD Million), 2021 & 2025 & 2032
Table 62. World Daptomycin API Production by Customer Business Model (2021-2026) & (kg)
Table 63. World Daptomycin API Production by Customer Business Model (2027-2032) & (kg)
Table 64. World Daptomycin API Production Value by Customer Business Model (2021-2026) & (USD Million)
Table 65. World Daptomycin API Production Value by Customer Business Model (2027-2032) & (USD Million)
Table 66. World Daptomycin API Average Price by Customer Business Model (2021-2026) & (US$/kg)
Table 67. World Daptomycin API Average Price by Customer Business Model (2027-2032) & (US$/kg)
Table 68. World Daptomycin API Production Value by Finished-dose, (USD Million), 2021 & 2025 & 2032
Table 69. World Daptomycin API Production by Finished-dose (2021-2026) & (kg)
Table 70. World Daptomycin API Production by Finished-dose (2027-2032) & (kg)
Table 71. World Daptomycin API Production Value by Finished-dose (2021-2026) & (USD Million)
Table 72. World Daptomycin API Production Value by Finished-dose (2027-2032) & (USD Million)
Table 73. World Daptomycin API Average Price by Finished-dose (2021-2026) & (US$/kg)
Table 74. World Daptomycin API Average Price by Finished-dose (2027-2032) & (US$/kg)
Table 75. Olon Basic Information, Manufacturing Base and Competitors
Table 76. Olon Major Business
Table 77. Olon Daptomycin API Product and Services
Table 78. Olon Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Olon Recent Developments/Updates
Table 80. Olon Competitive Strengths & Weaknesses
Table 81. Xellia Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 82. Xellia Pharmaceuticals Major Business
Table 83. Xellia Pharmaceuticals Daptomycin API Product and Services
Table 84. Xellia Pharmaceuticals Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Xellia Pharmaceuticals Recent Developments/Updates
Table 86. Xellia Pharmaceuticals Competitive Strengths & Weaknesses
Table 87. Livzon Group Fuzhou Fuxing Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 88. Livzon Group Fuzhou Fuxing Pharmaceutical Major Business
Table 89. Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API Product and Services
Table 90. Livzon Group Fuzhou Fuxing Pharmaceutical Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Livzon Group Fuzhou Fuxing Pharmaceutical Recent Developments/Updates
Table 92. Livzon Group Fuzhou Fuxing Pharmaceutical Competitive Strengths & Weaknesses
Table 93. Huadong Medicine Basic Information, Manufacturing Base and Competitors
Table 94. Huadong Medicine Major Business
Table 95. Huadong Medicine Daptomycin API Product and Services
Table 96. Huadong Medicine Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Huadong Medicine Recent Developments/Updates
Table 98. Huadong Medicine Competitive Strengths & Weaknesses
Table 99. Zhejiang Hisun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 100. Zhejiang Hisun Pharmaceutical Major Business
Table 101. Zhejiang Hisun Pharmaceutical Daptomycin API Product and Services
Table 102. Zhejiang Hisun Pharmaceutical Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Zhejiang Hisun Pharmaceutical Recent Developments/Updates
Table 104. Zhejiang Hisun Pharmaceutical Competitive Strengths & Weaknesses
Table 105. Zhejiang Medicine Basic Information, Manufacturing Base and Competitors
Table 106. Zhejiang Medicine Major Business
Table 107. Zhejiang Medicine Daptomycin API Product and Services
Table 108. Zhejiang Medicine Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Zhejiang Medicine Recent Developments/Updates
Table 110. Zhejiang Medicine Competitive Strengths & Weaknesses
Table 111. Chongqing Daxin Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 112. Chongqing Daxin Pharmaceutical Major Business
Table 113. Chongqing Daxin Pharmaceutical Daptomycin API Product and Services
Table 114. Chongqing Daxin Pharmaceutical Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Chongqing Daxin Pharmaceutical Recent Developments/Updates
Table 116. Chongqing Daxin Pharmaceutical Competitive Strengths & Weaknesses
Table 117. Lunan New Times Biotechnology Basic Information, Manufacturing Base and Competitors
Table 118. Lunan New Times Biotechnology Major Business
Table 119. Lunan New Times Biotechnology Daptomycin API Product and Services
Table 120. Lunan New Times Biotechnology Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Lunan New Times Biotechnology Recent Developments/Updates
Table 122. Lunan New Times Biotechnology Competitive Strengths & Weaknesses
Table 123. Sichuan Novals Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 124. Sichuan Novals Pharmaceuticals Major Business
Table 125. Sichuan Novals Pharmaceuticals Daptomycin API Product and Services
Table 126. Sichuan Novals Pharmaceuticals Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Sichuan Novals Pharmaceuticals Recent Developments/Updates
Table 128. Sichuan Novals Pharmaceuticals Competitive Strengths & Weaknesses
Table 129. Fujian Comhony Biotechnology Basic Information, Manufacturing Base and Competitors
Table 130. Fujian Comhony Biotechnology Major Business
Table 131. Fujian Comhony Biotechnology Daptomycin API Product and Services
Table 132. Fujian Comhony Biotechnology Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Fujian Comhony Biotechnology Recent Developments/Updates
Table 134. Fujian Comhony Biotechnology Competitive Strengths & Weaknesses
Table 135. Suzhou Biosynergy Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 136. Suzhou Biosynergy Pharmaceutical Major Business
Table 137. Suzhou Biosynergy Pharmaceutical Daptomycin API Product and Services
Table 138. Suzhou Biosynergy Pharmaceutical Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Suzhou Biosynergy Pharmaceutical Recent Developments/Updates
Table 140. Suzhou Biosynergy Pharmaceutical Competitive Strengths & Weaknesses
Table 141. North China Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 142. North China Pharmaceutical Major Business
Table 143. North China Pharmaceutical Daptomycin API Product and Services
Table 144. North China Pharmaceutical Daptomycin API Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. North China Pharmaceutical Recent Developments/Updates
Table 146. North China Pharmaceutical Competitive Strengths & Weaknesses
Table 147. Global Key Players of Daptomycin API Upstream (Raw Materials)
Table 148. Global Daptomycin API Typical Customers
Table 149. Daptomycin API Typical Distributors

LIST OF FIGURES

Figure 1. Daptomycin API Picture
Figure 2. World Daptomycin API Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Daptomycin API Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Daptomycin API Production (2021-2032) & (kg)
Figure 5. World Daptomycin API Average Price (2021-2032) & (US$/kg)
Figure 6. World Daptomycin API Production Value Market Share by Region (2021-2032)
Figure 7. World Daptomycin API Production Market Share by Region (2021-2032)
Figure 8. China Daptomycin API Production (2021-2032) & (kg)
Figure 9. Europe Daptomycin API Production (2021-2032) & (kg)
Figure 10. North America Daptomycin API Production (2021-2032) & (kg)
Figure 11. Daptomycin API Market Drivers
Figure 12. Factors Affecting Demand
Figure 13. World Daptomycin API Consumption (2021-2032) & (kg)
Figure 14. World Daptomycin API Consumption Market Share by Region (2021-2032)
Figure 15. United States Daptomycin API Consumption (2021-2032) & (kg)
Figure 16. China Daptomycin API Consumption (2021-2032) & (kg)
Figure 17. Europe Daptomycin API Consumption (2021-2032) & (kg)
Figure 18. Japan Daptomycin API Consumption (2021-2032) & (kg)
Figure 19. South Korea Daptomycin API Consumption (2021-2032) & (kg)
Figure 20. ASEAN Daptomycin API Consumption (2021-2032) & (kg)
Figure 21. India Daptomycin API Consumption (2021-2032) & (kg)
Figure 22. Producer Shipments of Daptomycin API by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 23. Global Four-firm Concentration Ratios (CR4) for Daptomycin API Markets in 2025
Figure 24. Global Four-firm Concentration Ratios (CR8) for Daptomycin API Markets in 2025
Figure 25. United States VS China: Daptomycin API Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 26. United States VS China: Daptomycin API Production Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Daptomycin API Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States Based Manufacturers Daptomycin API Production Market Share 2025
Figure 29. China Based Manufacturers Daptomycin API Production Market Share 2025
Figure 30. Rest of World Based Manufacturers Daptomycin API Production Market Share 2025
Figure 31. World Daptomycin API Production Value by Purity, (USD Million), 2021 & 2025 & 2032
Figure 32. World Daptomycin API Production Value Market Share by Purity in 2025
Figure 33. ≥99%
Figure 34. <99%
Figure 35. World Daptomycin API Production Market Share by Purity (2021-2032)
Figure 36. World Daptomycin API Production Value Market Share by Purity (2021-2032)
Figure 37. World Daptomycin API Average Price by Purity (2021-2032) & (US$/kg)
Figure 38. World Daptomycin API Production Value by Manufacturing Technology, (USD Million), 2021 & 2025 & 2032
Figure 39. World Daptomycin API Production Value Market Share by Manufacturing Technology in 2025
Figure 40. Conventional Fed-batch
Figure 41. High-titer Optimized Fermentation
Figure 42. World Daptomycin API Production Market Share by Manufacturing Technology (2021-2032)
Figure 43. World Daptomycin API Production Value Market Share by Manufacturing Technology (2021-2032)
Figure 44. World Daptomycin API Average Price by Manufacturing Technology (2021-2032) & (US$/kg)
Figure 45. World Daptomycin API Production Value by Customer Business Model, (USD Million), 2021 & 2025 & 2032
Figure 46. World Daptomycin API Production Value Market Share by Customer Business Model in 2025
Figure 47. Independent Generic Injectable Manufacturers
Figure 48. Vertically Integrated Pharmaceutical Groups
Figure 49. Others
Figure 50. World Daptomycin API Production Market Share by Customer Business Model (2021-2032)
Figure 51. World Daptomycin API Production Value Market Share by Customer Business Model (2021-2032)
Figure 52. World Daptomycin API Average Price by Customer Business Model (2021-2032) & (US$/kg)
Figure 53. World Daptomycin API Production Value by Finished-dose, (USD Million), 2021 & 2025 & 2032
Figure 54. World Daptomycin API Production Value Market Share by Finished-dose in 2025
Figure 55. 500 mg/vial
Figure 56. 350 mg/vial
Figure 57. World Daptomycin API Production Market Share by Finished-dose (2021-2032)
Figure 58. World Daptomycin API Production Value Market Share by Finished-dose (2021-2032)
Figure 59. World Daptomycin API Average Price by Finished-dose (2021-2032) & (US$/kg)
Figure 60. Daptomycin API Industry Chain
Figure 61. Daptomycin API Procurement Model
Figure 62. Daptomycin API Sales Model
Figure 63. Daptomycin API Sales Channels, Direct Sales, and Distribution
Figure 64. Methodology
Figure 65. Research Process and Data Source